Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.

Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA.

J Addict Med. 2013 Mar-Apr;7(2):102-7. doi: 10.1097/ADM.0b013e31827f9bdf.

2.

Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.

Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S14-21. doi: 10.1097/QAI.0b013e318209d3b9.

PMID:
21317589
3.

The medical management of opioid dependence in HIV primary care settings.

Lum PJ, Tulsky JP.

Curr HIV/AIDS Rep. 2006 Nov;3(4):195-204. Review.

PMID:
17089480
4.

Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).

Palella FJ Jr, Armon C, Buchacz K, Chmiel JS, Novak RM, D'Aquila RT, Brooks JT; HOPS Investigators.

J Antimicrob Chemother. 2014 Oct;69(10):2826-34. doi: 10.1093/jac/dku190. Epub 2014 Jun 16.

PMID:
24942257
5.

HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.

Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, Krishna N, Teshale EH, Paz-Bailey G; National HIV Behavioral Surveillance System Study Group.

MMWR Surveill Summ. 2014 Jul 4;63(6):1-51.

6.

Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

Baker JR, Best AM, Pade PA, McCance-Katz EF.

Ann Pharmacother. 2006 Mar;40(3):392-6. Epub 2006 Feb 28.

PMID:
16507617
7.

Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.

Sungkanuparph S, Sukasem C, Kiertiburanakul S, Pasomsub E, Chantratita W.

J Int AIDS Soc. 2012 Mar 12;15(1):12. doi: 10.1186/1758-2652-15-12.

8.

A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.

Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G.

MedGenMed. 2006 Jun 13;8(2):72.

9.

Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample.

McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW.

J Psychoactive Drugs. 2012 Jul-Aug;44(3):237-42.

10.

Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.

Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA.

Addiction. 2005 Feb;100(2):150-8. Review.

PMID:
15679744
11.

Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development.

Tassiopoulos K, Moscicki AB, Mellins C, Kacanek D, Malee K, Allison S, Hazra R, Siberry GK, Smith R, Paul M, Van Dyke RB, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study.

Clin Infect Dis. 2013 Jan;56(2):283-90. doi: 10.1093/cid/cis816. Epub 2012 Nov 7.

12.

Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics.

Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH.

Contemp Clin Trials. 2009 Sep;30(5):481-9. doi: 10.1016/j.cct.2009.05.003. Epub 2009 Jun 6.

13.

High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.

Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ.

AIDS Res Hum Retroviruses. 2004 Apr;20(4):355-64.

PMID:
15157354
14.

Antiretroviral (ARV) drug resistance in the developing world.

Shekelle P, Maglione M, Geotz MB, Wagner G, Wang Z, Hilton L, Carter J, Chen S, Tringle C, Mojica W, Newberry S.

Evid Rep Technol Assess (Full Rep). 2007 Sep;(156):1-74. Review.

15.
16.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
17.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.

18.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

19.

Sexual behaviors during antiretroviral therapy among HIV-infected patients, Thailand.

Lertpiriyasuwat C, Pradipasen M, Thiangtham W, Kaewduangjai P.

Southeast Asian J Trop Med Public Health. 2007 May;38(3):455-65.

PMID:
17877219
20.

Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care.

Rompalo AM, Shah N, Mayer K, Schuman P, Klein RS, Smith DK, Vlahov D.

J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):28-34.

PMID:
11579274

Supplemental Content

Support Center